Hypogonadism, Male Clinical Trial
Official title:
A Comparison of Side Effects in Hypogonadal Men Treated With Natesto Versus Testosterone Injections: A Phase IV, Prospective, Randomized, Non-Blinded, Multi-Institutional Study
The purpose of this study is to evaluate changes in vascular parameters and the prevalence of side effects in subjects receiving 1 cc (200mg) every 2 weeks intramuscular (IM) of Testosterone Cypionate versus subjects receiving 11mg three times daily (TID) Natesto to participant with clinical hypogonadism.
Administration of exogenous testosterone as efficacious treatment for male hypogonadism has been part of medical practice for more than 50 years. Testosterone replacement therapy (TRT) is becoming more widely available and has seen a greater than three-fold increase in use in men 40 years and older. Current delivery systems of TRT include transdermal gels and patches, intranasal gels (currently marketed as Natesto), injection therapy, and long acting subcutaneous pellets. Natesto is a short-acting formulation of testosterone delivered intranasally to men diagnosed with low T. This has the potential to avoid side effects related to TRT that are commonly seen with other delivery methods, namely polycythemia, acne, male-pattern hair loss, azoospermia and hyperestrogenemia. Testosterone Cypionate injections are the most common form of TRT in the USA. Testosterone Cypionate has many reported side effects, the most common being polycythemia, gynecomastia, hair loss, acne, decreased spermatogenesis, and testicular atrophy. In a multicenter retrospective study, it has been shown that the prevalence of polycythemia in men on testosterone replacement (injections) was 11.2%. In this study, we will compare hematocrit changes caused by treatment with Testosterone Cypionate and Natesto in a parallel arm, randomized study. To date, there have been no direct head-to-haed comparisons of these formulations. We hypothesize that the short-acting pharmacokinetics of Natesto more closely resembles the natural pulsatility of testosterone and therefore can avoid side effects traditionally seen in long-acting, exogenous testosterone formulations ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04467697 -
Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men
|
Phase 3 | |
| Completed |
NCT04326673 -
Salivary Testosterone in Men: Diurnal Variation and Post-Prandial Responses
|
||
| Completed |
NCT03203681 -
Natesto Effects on Testosterone, Luteinizing Hormone, Follicle Stimulating Hormone and Semen Parameters
|
Phase 4 | |
| Completed |
NCT01904734 -
Clomid in Men With Low Testosterone With and Without Prior Treatment
|
Phase 2 | |
| Completed |
NCT00398580 -
28-Day Study of Testosterone Co-administered With Dutasteride in Hypogonadal Men
|
Phase 2 | |
| Completed |
NCT00400335 -
Study On Bioavailability And Pharmacokinetics Of Various Doses Of Testosterone Administered With And Without Dutasteride
|
Phase 1 | |
| Recruiting |
NCT05611307 -
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
|
||
| Completed |
NCT03282682 -
Strength Training as a Supplemental Therapy of Androgen Deficiency of the Aging Male
|
N/A | |
| Terminated |
NCT03335254 -
A Phase 1/2a Study to Determine the Dose Response Pharmacokinetics of TSX-011 (Testosterone Undecanoate) in Hypogonadal Males
|
Phase 1/Phase 2 | |
| Terminated |
NCT05205837 -
A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial
|
Phase 4 | |
| Completed |
NCT03747003 -
Gonadal Function in Young to Middle Aged HIV-infected Men
|
||
| Withdrawn |
NCT03176537 -
Periodontal Profile of Hypogonadic Men
|
Phase 4 | |
| Recruiting |
NCT04049331 -
Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
|
Phase 2 | |
| Completed |
NCT03541395 -
Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males
|
N/A | |
| Recruiting |
NCT05249634 -
Testosterone Treatment in Men With Chronic Kidney Disease
|
Phase 2 | |
| Not yet recruiting |
NCT05773183 -
Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men
|
||
| Withdrawn |
NCT04717362 -
The Effects of Natesto For Treatment Of Hypogonadism
|
Early Phase 1 | |
| Completed |
NCT05806723 -
Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic Men
|
Phase 4 | |
| Completed |
NCT04456296 -
A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism
|
Phase 4 | |
| Not yet recruiting |
NCT06312761 -
Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17
|
Phase 1/Phase 2 |